Eugene Sun

7.4k total citations · 1 hit paper
67 papers, 4.9k citations indexed

About

Eugene Sun is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Eugene Sun has authored 67 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Infectious Diseases, 31 papers in Virology and 15 papers in Molecular Biology. Recurrent topics in Eugene Sun's work include HIV/AIDS drug development and treatment (33 papers), HIV Research and Treatment (31 papers) and HIV/AIDS Research and Interventions (20 papers). Eugene Sun is often cited by papers focused on HIV/AIDS drug development and treatment (33 papers), HIV Research and Treatment (31 papers) and HIV/AIDS Research and Interventions (20 papers). Eugene Sun collaborates with scholars based in United States, United Kingdom and China. Eugene Sun's co-authors include Dale J. Kempf, Martin King, John M. Leonard, James H. McKerrow, Anthony J. Japour, Barry Bernstein, Ann Hsu, Richard A. Rode, Scott Brun and Philip Rosenthal and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Eugene Sun

65 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

2002 518 citations Sharon Walmsley, Barry Bernstein et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eugene Sun United States	31	3.7k	2.9k	812	620	459	67	4.9k
Sophie Matheron France	39	2.7k 0.7×	2.2k 0.8×	462 0.6×	1.8k 2.9×	317 0.7×	203	5.0k
Richard M. W. Hoetelmans Netherlands	42	4.2k 1.2×	3.1k 1.1×	768 0.9×	949 1.5×	446 1.0×	139	5.2k
Gerd Fätkenheuer Germany	44	3.5k 1.0×	2.4k 0.8×	657 0.8×	1.6k 2.6×	604 1.3×	207	6.4k
Hedy Teppler United States	31	3.2k 0.9×	1.9k 0.7×	599 0.7×	1.3k 2.2×	399 0.9×	72	4.2k
Daniel S. Stein United States	34	1.9k 0.5×	1.3k 0.5×	377 0.5×	1.1k 1.7×	246 0.5×	92	3.0k
Patrick Yéni France	31	6.8k 1.9×	5.3k 1.8×	1.7k 2.0×	2.1k 3.4×	494 1.1×	89	8.5k
Markus Flepp Switzerland	33	4.1k 1.1×	2.8k 0.9×	1.0k 1.3×	2.0k 3.3×	184 0.4×	74	5.6k
Stefano Rusconi Italy	28	2.1k 0.6×	1.6k 0.6×	542 0.7×	581 0.9×	354 0.8×	204	3.0k
Oscar L. Laskin United States	25	2.8k 0.8×	2.1k 0.7×	384 0.5×	2.3k 3.7×	695 1.5×	43	5.7k
Emanuele Nicastri Italy	39	3.2k 0.9×	1.4k 0.5×	326 0.4×	1.4k 2.3×	850 1.9×	263	5.8k

Countries citing papers authored by Eugene Sun

Since Specialization

Citations

This map shows the geographic impact of Eugene Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugene Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugene Sun more than expected).

Fields of papers citing papers by Eugene Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugene Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugene Sun. The network helps show where Eugene Sun may publish in the future.

Co-authorship network of co-authors of Eugene Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Eugene Sun. A scholar is included among the top collaborators of Eugene Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugene Sun. Eugene Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Minji, Kyung‐Sook Chung, Jong Kil Lee, et al.. (2025). Immunomodulatory Effects of a Standardized Botanical Mixture Comprising Angelica gigas Roots and Pueraria lobata Flowers Through the TLR2/6 Pathway in RAW 264.7 Macrophages and Cyclophosphamide-Induced Immunosuppression Mice. Pharmaceuticals. 18(3). 336–336.

Lombardi, Antonio, et al.. (2025). Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants. Antimicrobial Agents and Chemotherapy. 69(4). e0154224–e0154224. 2 indexed citations

Janssen, Saskia, Caryn M. Upton, Veronique de Jager, et al.. (2025). Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond. American Journal of Respiratory and Critical Care Medicine. 211(8). 1504–1512. 3 indexed citations

Sun, Eugene, et al.. (2023). Zengshengping improves lung cancer by regulating the intestinal barrier and intestinal microbiota. Frontiers in Pharmacology. 14. 1123819–1123819. 11 indexed citations

Timm, Juliano, Matthew Bates, Adam A. Witney, et al.. (2023). Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. SHILAP Revista de lepidopterología. 3(10). e0002283–e0002283. 24 indexed citations

Hoover, Randall, Thomas L. Hunt, Susan K. Paulson, et al.. (2015). Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Clinical Therapeutics. 38(1). 39–52. 44 indexed citations

Hoover, Randall, Thomas L. Hunt, Susan K. Paulson, et al.. (2015). Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. Clinical Therapeutics. 38(1). 53–65. 45 indexed citations

Jiang, Jun, Jie Li, Zhenhai Zhang, et al.. (2015). Mechanism of enhanced antiosteoporosis effect of circinal–icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate. International Journal of Nanomedicine. 10. 2377–2377. 19 indexed citations

Eron, Joseph J., Judith Feinberg, Harold A. Kessler, et al.. (2004). Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial. The Journal of Infectious Diseases. 189(2). 265–272. 104 indexed citations

10.

King, Martin, Barry Bernstein, Sharon Walmsley, et al.. (2004). Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive Patients. The Journal of Infectious Diseases. 190(2). 280–284. 28 indexed citations

11.

Sáez‐Llorens, Xavier, Richard A. Rode, Edward Handelsman, et al.. (2003). . The Pediatric Infectious Disease Journal. 22(3). 216–223. 5 indexed citations

12.

Sáez‐Llorens, Xavier, Richard A. Rode, Perry Gomez, et al.. (2003). Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. The Pediatric Infectious Disease Journal. 22(3). 216–223. 102 indexed citations

13.

Mo, Hongmei, Liangjun Lu, Tatyana Dekhtyar, et al.. (2003). Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antiviral Research. 59(3). 173–180. 27 indexed citations

14.

Bertz, Richard, Barry Bernstein, Yi‐Lin Chiu, et al.. (2002). Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. 42. 26. 5 indexed citations

15.

Walmsley, Sharon, Barry Bernstein, Martin King, et al.. (2002). Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection. New England Journal of Medicine. 346(26). 2039–2046. 518 indexed citations breakdown →

16.

Gustavson, Linda E., Richard Bertz, Ann Hsu, et al.. (2000). Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir in healthy subjects. 40. 338. 8 indexed citations

17.

Bertz, Richard, et al.. (2000). Assessment of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV + subjects. 40. 14. 1 indexed citations

18.

Churchill, Duncan, Alexander S. Pym, S. Galpin, et al.. (1999). The Rabbit Study: Ritonavir and Saquinavir in Combination in Saquinavir-Experienced and Previously Untreated Patients. AIDS Research and Human Retroviruses. 15(13). 1181–1189. 5 indexed citations

19.

Kumar, Deepak, et al.. (1999). Sustained Suppression of Plasma HIV RNA Is Associated with an Increase in the Production of Mitogen-Induced MIP-1alpha and MIP-1beta. AIDS Research and Human Retroviruses. 15(12). 1073–1077. 17 indexed citations

20.

Cameron, D. William, Margo Heath‐Chiozzi, Sven A. Danner, et al.. (1998). Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Lancet. 351(9102). 543–549. 427 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact